Trials / Completed
CompletedNCT01325441
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 565 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
Detailed description
This is an open label, multi-center, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced solid tumors for whom weekly paclitaxel is an acceptable option.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBI608 | |
| DRUG | Paclitaxel |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
- First posted
- 2011-03-29
- Last updated
- 2023-11-15
- Results posted
- 2023-02-03
Locations
22 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01325441. Inclusion in this directory is not an endorsement.